Figure 2

Antigen, IgG, IgM, and outcome profiles in suspected LASV patient sera from the first study (December 2009): G079-3 through G617-1. A. Trad Ag, IgG, IgM (USAMRIID), and r Ag, IgG, IgM (Hemorrhagic Fever Virus Diagnostics Consortium) were ELISA platforms, whereas GP1, GP2, NP WB were western blots. The USAMRIID assays were performed before the recombinant counterparts, sometimes months in advance. Western blot analyses were performed on samples shipped to the U.S. following irradiation. A very strong positive signal is indicated by ++ and a positive by +. Marginal positive detection is indicated by +/- and negatives by -. Gray boxes indicate that relevant data was not collected for the corresponding sample. Patient outcomes recorded in databases are: d, discharged; D, dead; na, not admitted; c, household contact of patient G676; ?, patient samples from Liberia, with unknown outcome. Non applicable (N/a) outcome is indicated for in vitro controls. B. Traditional antigen (Trad Ag) data showing the A450 O.D. for all samples (blue) alongside positive (dark red) and negative (green) controls. Data are plotted as mean ± SD, n = 2. Each sample in this series was analyzed on different days, concurrent with testing of suspect patients admitted to KGH. Collection dates for this series ranged from January 2008 to September 2009.